// App-Quantinova.ai

3014 : Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.

Researchers

Presenter

  • Antoni Ribas

Principal Investigators

  • F. Stephen Hodi

  • Donald P. Lawrence

  • Victoria Atkinson

  • Alexander Starodub

  • Matteo S. Carlino

  • Rosalie Anne Fisher

  • Georgina V. Long

  • Wilson H Miller

  • Yingjie Huang

  • Scott J. Diede

  • Scot Ebbinghaus

  • Omid Hamid

Medical Centers

  • University of California, Los Angeles, Los Angeles, CA

  • Dana-Farber Cancer Institute, Boston, MA

  • Massachusetts General Hospital, Boston, MA

  • Gallipoli Medical Research Foundation and Greenslopes Private Hospital, Brisbane, Australia

  • Indiana University Health Center for Cancer Care, Goshen, IN

  • Westmead and Blacktown Hospitals, Melanoma Institute Australia, Sydney, Australia

  • Auckland City Hospital, Auckland, New Zealand

  • Melanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, Australia

  • Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada

  • Novartis, East Hanover, NJ

  • Merck & Co., Inc., Kenilworth, NJ

  • The Angeles Clinic and Research Institute, Los Angeles, CA

Locations

  • United States

  • Canada

  • New Zealand

  • Australia

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02130466

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved